Antenatal Micronutrient Supplementation and Infant Survival

NCT00860470 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 44567

Last updated 2022-10-19

Study results available
· View outcomes & findings →

Summary

The purpose of this community-based randomized trial is to examine whether a daily antenatal and postnatal multiple micronutrient supplement given to women will enhance newborn and infant survival and health and other birth outcomes in a rural setting in northwestern Bangladesh.

Conditions

Interventions

DIETARY_SUPPLEMENT

Iron (27 mg) - folic acid (600 ug)

Supplement serves as the "Control" (providing the current standard of care during pregnancy). Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum.

DIETARY_SUPPLEMENT

Multiple micronutrient

Containing 15 micronutrients all at an RDA including: vitamin A (770 ug retinol equivalents, vitamin D (5 ug), vitamin E (15 mg), folic acid (600 ug), thiamin (1.4 mg), riboflavin (1.4 mg), niacin (18 mg), vitamin B-12 (2.6 mg), vitamin B-6 (1.9 mg), vitamin C (85 mg), iron (27 mg), zinc (12 mg), iodine (220 ug), copper (1000 ug), selenium (60 ug). Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum.

Sponsors & Collaborators

  • Bill and Melinda Gates Foundation

    collaborator OTHER
  • United States Agency for International Development (USAID)

    collaborator FED
  • Mahidol University

    collaborator OTHER
  • Johns Hopkins University

    collaborator OTHER
  • Beximco Pharmaceuticals Ltd.

    collaborator INDUSTRY
  • DSM Nutritional Products, Inc.

    collaborator INDUSTRY
  • Johns Hopkins Bloomberg School of Public Health

    lead OTHER

Principal Investigators

  • Keith P West, Jr. · Johns Hopkins Bloomberg School of Public Health

  • Parul Christian · Johns Hopkins Bloomberg School of Public Health

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United States
  • Bangladesh

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00860470 on ClinicalTrials.gov